Navin, N. E. The first five years of single-cell cancer genomics and beyond. Genome Res. 25, 1499–1507 (2015).
Google Scholar
Schmitt, M. W. et al. Single-molecule sequencing reveals patterns of pre-existing drug resistance that suggest treatment strategies in Philadelphia-positive leukemias. Clin. Cancer Res. 24, 5321–5334 (2018).
Google Scholar
Frankell, A. M. et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature 616, 525–533 (2023).
Google Scholar
Martínez-Ruiz, C. et al. Genomic–transcriptomic evolution in lung cancer and metastasis. Nature 616, 543–552 (2023).
Google Scholar
Song, P. et al. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nat. Biomed. Eng. 6, 232–245 (2022).
Google Scholar
Short, N. J. et al. Ultra-accurate duplex sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J. 10, 1–9 (2020).
Google Scholar
Leighow, S. M. & Pritchard, J. R. The risks of perpetuating an evolutionary arms race in drug discovery. Evol. Med. Public Health 2019, 64–65 (2019).
Google Scholar
Leonetti, A. et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br. J. Cancer 121, 725–737 (2019).
Google Scholar
Bozic, I. et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2, e00747 (2013).
Google Scholar
Goldie, J. H. & Coldman, A. J. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 44, 3643–3653 (1984).
Google Scholar
Frei, E. Curative cancer chemotherapy. Cancer Res. 45, 6523–6537 (1985).
Google Scholar
Palmer, A. C., Chidley, C. & Sorger, P. K. A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity. eLife 8, e50036 (2019).
Google Scholar
Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. Nature 568, 511–516 (2019).
Google Scholar
Meyers, R. M. et al. Computational correction of copy-number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017).
Google Scholar
US Food and Drug Administration. FDA Approves Osimertinib with Chemotherapy for EGFR-Mutated Non-small Cell Lung Cancer (FDA, 2024).
Corrie, P. G. Cytotoxic chemotherapy: clinical aspects. Medicine 36, 24–28 (2008).
Google Scholar
Wang, Y. et al. Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study. BMC Cancer 14, 940 (2014).
Google Scholar
Noronha, V. et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J. Clin. Oncol. 38, 124–136 (2020).
Google Scholar
Planchard, D. et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N. Engl. J. Med. 389, 1935–1948 (2023).
Google Scholar
Offin, M. et al. Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin. Cancer Res. 25, 1063–1069 (2019).
Google Scholar
Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
Google Scholar
Nasu, Y. et al. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol. Ther. J. Am. Soc. Gene Ther. 15, 834–840 (2007).
Google Scholar
Topf, N., Worgall, S., Hackett, N. R. & Crystal, R. G. Regional ‘pro-drug’ gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther. 5, 507–513 (1998).
Google Scholar
Patel, P. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol. Ther. J. Am. Soc. Gene Ther. 17, 1292–1299 (2009).
Google Scholar
Rainov, N. G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11, 2389–2401 (2000).
Google Scholar
Sangro, B. et al. A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther. 17, 837–843 (2010).
Google Scholar
Sagara, T. et al. Successful gene therapy requires targeting the vast majority of cancer cells. Cancer Biol. Ther. 21, 946–953 (2020).
Google Scholar
Windbichler, N. et al. A synthetic homing endonuclease-based gene drive system in the human malaria mosquito. Nature 473, 212–215 (2011).
Google Scholar
Allen, G. M. & Lim, W. A. Rethinking cancer targeting strategies in the era of smart cell therapeutics. Nat. Rev. Cancer 22, 693–702 (2022).
Google Scholar
Zhang, J., Kale, V. & Chen, M. Gene-directed enzyme prodrug therapy. AAPS J. 17, 102–110 (2014).
Google Scholar
ElOjeimy, S. et al. FasL gene therapy: a new therapeutic modality for head and neck cancer. Cancer Gene Ther. 13, 739–745 (2006).
Google Scholar
Touraine, R. L., Ishii-Morita, H., Ramsey, W. J. & Blaese, R. M. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther. 5, 1705–1711 (1998).
Google Scholar
Rollins, C. T. et al. A ligand-reversible dimerization system for controlling protein–protein interactions. Proc. Natl Acad. Sci. USA 97, 7096–7101 (2000).
Google Scholar
Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673–1683 (2011).
Google Scholar
Iuliucci, J. D. et al. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J. Clin. Pharmacol. 41, 870–879 (2001).
Google Scholar
Jura, N. et al. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 137, 1293–1307 (2009).
Google Scholar
Lin, J. H. Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy. Curr. Drug Metab. 8, 109–136 (2007).
Google Scholar
Subbiah, V. et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat. Med. 28, 1640–1645 (2022).
Google Scholar
Subbiah, V. et al. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann. Oncol. 32, 261–268 (2021).
Google Scholar
Cloughesy, T. F. et al. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro Oncol. 20, 1383–1392 (2018).
Google Scholar
Pandha, H. S. et al. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J. Clin. Oncol. 17, 2180–2189 (1999).
Google Scholar
Vermes, A., Guchelaar, H.-J. & Dankert, J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 46, 171–179 (2000).
Google Scholar
Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330–338 (2003).
Google Scholar
Fuchita, M. et al. Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo. Cancer Res. 69, 4791–4799 (2009).
Google Scholar
Pardini, B. et al. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. Br. J. Clin. Pharmacol. 72, 162–163 (2011).
Google Scholar
Gilad, Y., Gellerman, G., Lonard, D. M. & O’Malley, B. W. Drug combination in cancer treatment—from cocktails to conjugated combinations. Cancers 13, 669 (2021).
Google Scholar
Freytag, S. O. et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 63, 7497–7506 (2003).
Google Scholar
Upadhyay, R. et al. A critical role for fas-mediated off-target tumor killing in T cell immunotherapy. Cancer Discov. 11, 599–613 (2021).
Google Scholar
Janopaul-Naylor, J. R., Shen, Y., Qian, D. C. & Buchwald, Z. S. The abscopal effect: a review of pre-clinical and clinical advances. Int. J. Mol. Sci. 22, 11061 (2021).
Google Scholar
Roth, J. A. et al. Retrovirus-mediated wild-type P53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2, 985–991 (1996).
Google Scholar
Soria, J.-C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113–125 (2018).
Google Scholar
Kamiyama, D. et al. Versatile protein tagging in cells with split fluorescent protein. Nat. Commun. 7, 11046 (2016).
Google Scholar
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
Google Scholar
Dempster, J. M. et al. Extracting biological insights from the Project Achilles genome-scale CRISPR screens in cancer cell lines. Preprint at bioRxiv https://doi.org/10.1101/720243 (2019).
Zeng, H. et al. Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC. eLife 8, e50223 (2019).
Google Scholar
Maley, C. C., Reid, B. J. & Forrest, S. Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiol. Biomark. Prev. 13, 1375–1384 (2004).
Google Scholar
Freeman, S. M. et al. The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274–5283 (1993).
Google Scholar
Gatenby, R. A., Silva, A. S., Gillies, R. J. & Frieden, B. R. Adaptive therapy. Cancer Res. 69, 4894–4903 (2009).
Google Scholar
Zhang, J., Cunningham, J. J., Brown, J. S. & Gatenby, R. A. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat. Commun. 8, 1816 (2017).
Google Scholar
Lin, K. H. et al. Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer. Nat. Genet. 52, 408–417 (2020).
Google Scholar
Zhao, B. et al. Exploiting temporal collateral sensitivity in tumor clonal evolution. Cell 165, 234–246 (2016).
Google Scholar
Chen, G. et al. Targeting the adaptability of heterogeneous aneuploids. Cell 160, 771–784 (2015).
Google Scholar
Dalin, S., Grauman-Boss, B., Lauffenburger, D. A. & Hemann, M. T. Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse. Sci. Rep. 12, 5453 (2022).
Google Scholar
Körbelin, J. et al. Pulmonary targeting of adeno-associated viral vectors by next-generation sequencing-guided screening of random capsid displayed peptide libraries. Mol. Ther. 24, 1050–1061 (2016).
Google Scholar
Goertsen, D., Goeden, N., Flytzanis, N. C. & Gradinaru, V. Targeting the lung epithelium after intravenous delivery by directed evolution of underexplored sites on the AAV capsid. Mol. Ther. Methods Clin. Dev. 26, 331–342 (2022).
Google Scholar
Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020).
Google Scholar
Nemunaitis, J. et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol. Ther. J. Am. Soc. Gene Ther. 18, 429–434 (2010).
Google Scholar
Liu, X., Ding, J. & Meng, L. Oncogene-induced senescence: a double edged sword in cancer. Acta Pharmacol. Sin. 39, 1553–1558 (2018).
Google Scholar
Kim, M.-Y. et al. Tumor self-seeding by circulating cancer cells. Cell 139, 1315–1326 (2009).
Google Scholar
Zhu, H. et al. Oncogene-induced senescence: from biology to therapy. Mech. Ageing Dev. 187, 111229 (2020).
Google Scholar
Mack, E. T., Perez-Castillejos, R., Suo, Z. & Whitesides, G. M. Exact analysis of ligand-induced dimerization of monomeric receptors. Anal. Chem. 80, 5550–5555 (2008).
Google Scholar
Wang, B. et al. Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute. Nat. Protoc. 14, 756–780 (2019).
Google Scholar
Therneau, T. M. & Grambsch, P. M. Modeling Survival Data: Extending the Cox Model (Springer, 2000).
pritchardlabatpsu/SelectionGeneDrives: Selection Gene Drive Code Release v1.0. GitHub https://doi.org/10.5281/zenodo.10840332 (2024).
Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR–Cas9. Nat. Biotechnol. 34, 184–191 (2016).
Google Scholar
Rodriguez de la Fuente, L., Law, A. M. K., Gallego-Ortega, D. & Valdes-Mora, F. Tumor dissociation of highly viable cell suspensions for single-cell omic analyses in mouse models of breast cancer. STAR Protoc. 2, 100841 (2021).
Google Scholar
Leighow, S. M. et al. Programming tumor evolution with selection gene drives to prevent the emergence of drug resistance. Datasets. NCBI Bioproject. NCBI https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA1081395 (2024).
